Home » CTI announces promotion of VP, regulatory affairs study start up

CTI announces promotion of VP, regulatory affairs study start up

Günter Stetter

COVINGTON, Ky. — CTI Clinical Trial and Consulting Services, a multi-national, privately-held, full-service contract research organization, has promoted Günter Stetter to vice president, global regulatory affairs study start up.

“We are thrilled to announce Günter’s promotion,” said Kevin Schwarz, chief operating officer. “Günter has played a critical role in the growth of our company throughout his eight years with the company, leading our operational team through a period of significant growth in both employees and projects. We look forward to his continued contributions as the leader of the Global Regulatory Affairs Study Start Up department.”

Stetter has been with CTI since 2010, quickly rising to the position of senior director, clinical operations, Europe. He has been instrumental in the growth of the European clinical operations team, and regularly serves as the go-to person regarding European affairs for both internal team members and our sponsors.

Stetter has more than 30 years of clinical, academic and industry experience, with the majority of those years spent successfully planning and managing multinational clinical trial programs across all phases and in multiple therapeutic areas.

Prior to joining CTI, Stetter was director of clinical operations for AAIPharma Deutschland GmbH & Co. KG Neu-Ulm, and spent time as a project manager and study manager for Rentschler Biotechnologie GmbH and Rentschler Arzneimittel GmbH & Co. KG. He began his career as an assistant professor of biochemistry at the Universität Ulm, and obtained a doctor of science and a master of science (Biology) from the Universität Ulm.